Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego
NCT ID: NCT03551002
Last Updated: 2021-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
450 participants
OBSERVATIONAL
2018-01-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity
NCT04729153
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
NCT01743521
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
NCT03197155
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
NCT02102451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective
No interventions assigned to this group
Prospective
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edward Cachay, MD, MAS
Associate Professor of Clinical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward Cachay, MD, MAS
Role: PRINCIPAL_INVESTIGATOR
University of California, San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Owen Clinic-University of California, San Diego
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
171954
Identifier Type: OTHER
Identifier Source: secondary_id
IN-US-334-4481
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.